Cardiovascular disease in patients with type 2 diabetes

Article Endocrinology & Metabolism

Clinical inertia in patients with type 2 diabetes treated with oral antidiabetic drugs: Results from a Japanese cohort study (JDDM53)

Hiroshi Maegawa et al.

Summary: This study reveals the presence of clinical inertia in Japanese adults with type 2 diabetes, highlighting the need for earlier and more effective treatment intensification.

JOURNAL OF DIABETES INVESTIGATION (2021)

Add to Collection

Review Endocrinology & Metabolism

Sodium-glucose cotransporter 2 inhibitors represent a paradigm shift in the prevention of heart failure in type 2 diabetes patients

Atsunori Kashiwagi et al.

Summary: Recent clinical trials have shown that SGLT2 inhibitors reduce cardiovascular events in type 2 diabetes patients. They are also beneficial for patients with a history of heart failure.

JOURNAL OF DIABETES INVESTIGATION (2021)

Add to Collection

Editorial Material Endocrinology & Metabolism

Sodium-glucose cotransporter 2 inhibitors: A drug with antidiabetic and cardioprotective properties

Hung-Yuan Li

JOURNAL OF DIABETES INVESTIGATION (2021)

Add to Collection

Article Endocrinology & Metabolism

Impact of daily glucose fluctuations on cardiovascular outcomes after percutaneous coronary intervention for patients with stable coronary artery disease undergoing lipid-lowering therapy

Hiroyuki Yamamoto et al.

Summary: The study suggests that daily glucose fluctuation may influence future cardiovascular events in lipid-controlled stable CAD patients.

JOURNAL OF DIABETES INVESTIGATION (2021)

Add to Collection

Editorial Material Endocrinology & Metabolism

Commentary on risk factors for first and subsequent cardiovascular disease events in type 1 diabetes: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study

Chun-Hsien Lin et al.

JOURNAL OF DIABETES INVESTIGATION (2021)

Add to Collection

Article Endocrinology & Metabolism

10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2021

Summary: The ADA Standards of Medical Care in Diabetes provides clinical practice recommendations and tools for evaluating quality of care. The Professional Practice Committee is responsible for updating the standards annually, and readers can comment on the standards on the official website.

DIABETES CARE (2021)

Add to Collection

Editorial Material Endocrinology & Metabolism

New prospects for incretin-related drugs in the treatment of type 2 diabetes

Tomohiko Kimura et al.

JOURNAL OF DIABETES INVESTIGATION (2021)

Add to Collection

Article Endocrinology & Metabolism

Cardiovascular events and mortality in people with and without type 2 diabetes: An observational study in a contemporary multi-ethnic population

Briana Coles et al.

Summary: Despite universal access to healthcare, there are large disparities in CVD outcomes in people with and without type 2 diabetes mellitus, with individuals of South Asian ethnicity having a higher CVD risk associated with type 2 diabetes mellitus. Other non-traditional risk factors may play a role in this association.

JOURNAL OF DIABETES INVESTIGATION (2021)

Add to Collection

Article Endocrinology & Metabolism

Trends in Cardiovascular Complications and Mortality among Patients with Diabetes in South Korea

Jung Hwan Park et al.

Summary: From 2006 to 2015, hospitalization rates for major cardiovascular complications decreased in South Korean diabetes patients, while rates for heart failure and peripheral artery disease increased. From 2007 to 2015, mortality rates for cancer, cerebrovascular disease, diabetes, heart disease, and hypertensive disease decreased, but mortality rate for pneumonia increased. Overall, there was a continuous reduction in cardiovascular complications and mortality in adults with diabetes, but efforts are needed to prevent certain diabetes complications.

DIABETES & METABOLISM JOURNAL (2021)

Add to Collection

Article Endocrinology & Metabolism

Risk of early mortality and cardiovascular disease according to the presence of recently diagnosed diabetes and requirement for insulin treatment: A nationwide study

You-Bin Lee et al.

Summary: In Korean adults, recently diagnosed type 2 diabetes patients have increased risks of cardiovascular diseases and premature mortality. Patients treated with insulin have even higher risks, indicating the need for intensified cardio-protective interventions.

JOURNAL OF DIABETES INVESTIGATION (2021)

Add to Collection

Article Endocrinology & Metabolism

Association between glycemic control and cardiovascular events in older Japanese adults with diabetes mellitus: An analysis of the Japanese medical administrative database

Koutaro Yokote et al.

Summary: The study investigated the relationship between glycated hemoglobin (HbA1c) and cardiovascular events in older adults with diabetes using a Japanese administrative medical database. It found that older adults with poor glycemic control were at higher risk for cardiovascular events compared to those with better glycemic control. However, strict glycemic control did not impact cardiovascular risk for patients with HbA1c <7.2%.

JOURNAL OF DIABETES INVESTIGATION (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs

Dario Giugliano et al.

Summary: Glucagon-like peptide-1 receptor agonists have significant benefits on cardiovascular and renal outcomes in patients with type 2 diabetes, including reducing major cardiovascular events, hospitalization for heart failure, all-cause mortality, and the incidence of macroalbuminuria.

CARDIOVASCULAR DIABETOLOGY (2021)

Add to Collection

Review Medicine, General & Internal

SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications

Emily Brown et al.

Summary: SGLT2 inhibitors and GLP-1 receptor agonists are effective in lowering glucose, weight loss, and blood pressure reduction, offering additional protection for cardiovascular disease in patients with type 2 diabetes. They are considered second-line therapies for diabetes, with prioritized consideration based on individual patient characteristics.

LANCET (2021)

Add to Collection

Article Endocrinology & Metabolism

Association of visit-to-visit glycemic variability with risk of cardiovascular diseases in high-risk Japanese patients with type 2 diabetes: A subanalysis of the EMPATHY trial

Midori Sato et al.

Summary: In Japanese patients with type 2 diabetes, long-term glycemic variability is associated with the risk of cardiovascular events, independent of mean-HbA1c. Variability and mean HbA1c could be important glycemic indicators in managing type 2 diabetes patients, especially for those with a mean-HbA1c of <7%.

JOURNAL OF DIABETES INVESTIGATION (2021)

Add to Collection

Article Endocrinology & Metabolism

Cardiovascular Safety of Sodium Glucose Cotransporter 2 Inhibitors as Add-on to Metformin Monotherapy in Patients with Type 2 Diabetes Mellitus

Ja Young Jeon et al.

Summary: A retrospective observational study in Korea found that SGLT2 inhibitors were associated with a lower risk of heart failure and mortality compared to DPP-4 inhibitors as second-line treatment, and also had decreased risks of cardiovascular outcomes when compared to sulfonylureas as add-on therapy to metformin in patients with type 2 diabetes mellitus.

DIABETES & METABOLISM JOURNAL (2021)

Add to Collection

Article Endocrinology & Metabolism